1 Impact of Diagnostic Stewardship on Ordering Trends and Pathogen Yield from

2 mNGS Studies

3

4 Running title: Impacts of mNGS Stewardship

5

- 6 Ryan C. Shean^{1,2,#}, Elizabeth Garrett^{3,#}, James Malleis⁴, Joshua A. Lieberman^{4*},
- 7 Benjamin T. Bradley^{1,2*}

8

- ⁹ ¹Department of Pathology, University of Utah, Salt Lake City, UT
- 10 ²ARUP Laboratories, Salt Lake City, UT
- ¹¹ ³Department of Pathology and Laboratory Medicine, The Pennsylvania State University,
- 12 Hershey, PA
- ¹³ ⁴Department of Laboratory Medicine and Pathology, University of Washington, Seattle,

14 WA

- ¹⁵ [#] These authors contributed equally to this work
- 16 *Co-corresponding authors, Benjamin T. Bradley, <u>ben.bradley@hsc.utah.edu</u>; Joshua
- 17 A. Lieberman, joshuaal@uw.edu
- 18 Keywords: stewardship, mNGS, microbiology, ordering practices, test utilization

19 Background

- 20 Given the cost and unclear clinical impact of metagenomic next-generation sequencing
- 21 (mNGS), laboratory stewardship may improve utilization. This study examines mNGS
- 22 results from two academic medical centers employing different stewardship
- 23 approaches.
- 24 <u>Methods</u>
- 80 mNGS orders (54 CSF and 26 plasma) were identified from 2019 to 2021 at the
- 26 University of Washington (UW), which requires director-level approval for mNGS orders,
- and the University of Utah (Utah), which does not restrict ordering. The impact of mNGS
- results and the relationship to traditional microbiology orders were retrospectively

29 evaluated.

- 30 <u>Results</u>
- 19% (10/54) CSF and 65% (17/26) plasma studies detected at least one organism.
- 32 Compared to CSF results, plasma results were more frequently clinically significant
- 33 (23% vs 7%) and led to more novel diagnoses (15% vs 0%). Results affecting antibiotic
- management were more common for plasma than CSF (32% vs. 2%). Stewardship
- 35 practices were not associated with statistically significant differences in results or
- 36 antimicrobial management. The number and cost of traditional microbiology tests at UW
- was greater than Utah for CSF mNGS testing (UW: 46 tests, \$6237; Utah: 26 tests,
- 38 \$2812; p<0.05) but similar for plasma mNGS (UW: 31 tests, \$3975; Utah: 21 tests,
- 39 \$2715; p=0.14). mNGS testing accounted for 30-50% of the total microbiology costs.
- 40 <u>Conclusions</u>

- 41 Improving the diagnostic performance of mNGS by stewardship remains challenging
- 42 due to low positivity rates and difficulties assessing clinical impact. From a fiscal
- 43 perspective, stewardship efforts should focus on reducing testing in low-yield
- 44 populations given the high costs of mNGS relative to overall microbiology testing
- 45 expenditures.

46 Introduction

Next-generation sequencing (NGS) is a powerful technology that allows for 47 millions of DNA fragments to be independently and simultaneously sequenced. 48 Metagenomic NGS (mNGS) is the analytical process by which all nucleic acid can be 49 sequenced and classified, permitting complex populations of nucleic acid from many 50 51 organisms to be analyzed in a single sample. These technologies have emerged as exciting, but expensive tools to diagnose infections from diverse anatomic sites and 52 specimen types, including cerebrospinal fluid (CSF) and plasma.¹⁻⁶ An advantage of 53 mNGS over traditional microbiological approaches is the ability to detect any bacterial, 54 viral, and fungal organism, without explicit inclusion in the provider's differential 55 diagnosis.^{3,7} This stands in contrast to traditional microbiology testing, including culture, 56 serology, and nucleic acid amplification tests, which depends on the provider's 57 differential diagnosis to help select the appropriate tests^{8,9}. Plasma mNGS can also 58 provide a non-invasive alternative to biopsy for the identification of deep infections such 59 as invasive fungal disease or osteomyelitis and occult infections such as culture-60 negative endocarditis.^{10–12} 61

However, the role of mNGS technology in infectious disease diagnostics and its place in the context of traditional microbiology testing is still unclear. As with other approaches, mNGS can identify clinically irrelevant targets such as colonizing or transient organisms. DNA can also persist well after an organism has been cleared; therefore, mNGS results must be interpreted in the context of the patient's clinical presentation.⁶ Recent studies have described variable clinical utility of mNGS results, finding 12-55% of positive results to be clinically actionable^{13,14}. This variable clinical

impact is due to the diverse range of patient populations, clinical syndromes, and 69 matrices that can be assessed with this unbiased diagnostic approach.^{10,14–16} 70 71 Interpretation of the results is further complicated by differences in the analytic techniques and databases used to classify nucleic acid sequences¹⁷. 72 Due to the novelty, cost, limited clinical impact, and difficulty in properly 73 74 interpreting mNGS results, a variety of stewardship practices have been implemented to improve test utilization¹⁸. Historically, diagnostic stewardship has been used in clinical 75 microbiology testing to counterbalance well-intentioned but misdirected use¹⁹. Some 76 77 successful implementations of diagnostic stewardship include decision support testing (e.g., hard stops on *Clostridioides difficile* testing on formed stool samples) as well as 78 automated reflex testing to ensure that proper algorithms are correctly followed²⁰. There 79 is a clear need for evidence-based guidance to help inform when mNGS infectious 80 disease testing will improve patient outcomes¹⁹. Currently available data show 81 diagnostic utility largely depends upon the use case in which mNGS is performed^{14,21,22}. 82 To properly inform diagnostic stewardship guidelines, data such as the cost, timing, and 83 context of mNGS ordering relative to traditional microbiology testing is needed. 84 85 In this retrospective analysis, we examined CSF and plasma mNGS orders in patients across two different multicenter hospital systems, which provide extensive 86 87 specialty care for cancer, transplant, and trauma patients. We evaluated mNGS assay 88 performance, impact on antibiotic management, and relationship to traditional microbiology testing in terms of timing and cost. We highlight the impact that 89 90 stewardship may have on these measures to aid laboratories in the establishment of 91 evidence-based guidelines.

92 Materials and Methods

93 <u>Ethics Statement</u>

This study was approved by the University of Washington (UW) Institutional
Review Board Committee (IRB ID STUDY00010777) and University of Utah (Utah)
Institutional Review Board (IRB 00151187) as waived research; informed consent was
not required.
<u>mNGS Testing</u>

CSF mNGS was performed by the University of California San Francisco Clinical
 Microbiology Lab (California); plasma mNGS was performed by Karius (Redwood City,
 California). Both laboratories are Clinical Laboratory Improvement Amendments (CLIA) certified. Samples were submitted in accordance with the specimen requirements for

103 each laboratory.

104 Institutional Approval Processes for mNGS

At UW, the interdisciplinary Laboratory Formulary Committee sets an annual limit 105 on the number of mNGS send-out tests and instituted an approval process. Briefly, 106 provider requests for CSF and plasma mNGS testing underwent a collaborative review 107 108 process between clinical microbiology directors and the care team with required input from infectious disease physicians. Considerations for approval included: 1) expected 109 110 impact to clinical decision making, 2) traditional microbiologic testing results (cultures, 111 serology, and nucleic acid amplification test (NAAT)), 3) clinical suspicion for infectious etiology, and 4) difficulty of obtaining lesional tissue. Extended factors included 112 113 underlying medical conditions, immunocompromised status, and recent antibiotic

exposure. At Utah, laboratory approval for CSF and plasma mNGS was not requiredprior to test ordering.

116 Data Collection and Analysis

Specimens approved for CSF or plasma mNGS testing at UW from July 2019 to 117 March 2021 and ordered at Utah from January 2019 to December 2021 were 118 119 retrospectively identified through the laboratory information systems (LIS). Patient charts were reviewed to determine the significance and impact of mNGS testing. Any 120 121 test result in which one or more organisms were detected by the assay were considered 122 a positive mNGS result. Clinically significant results were adjudicated based on review of the medical chart and impression of the clinical team caring for the patient. 123 Organisms known to cause latent infections (e.g. CMV, EBV) or part of the oral or 124 gastrointestinal flora (e.g., coagulase-negative staphylococci, viridians streptococci) 125 were considered clinically insignificant unless otherwise indicated by the medical team 126 127 or supported by orthogonal clinical testing. Novel pathogens were defined as organisms deemed clinically significant and not observed by orthogonal means prior to mNGS 128 results. Clinical impact was evaluated based on as alterations in antimicrobial treatment 129 130 (escalation, de-escalation, or change) that specifically considered mNGS results, positive or negative. Additional data were gathered from the LIS regarding patient 131 132 demographics and traditional microbiology orders placed. For this study's purposes, 133 traditional microbiology orders were considered any test (culture, serology, antigen, or molecular assay) ordered to assist in the clinical diagnosis excluding mNGS. 134 135 Surveillance and routine screening studies were excluded. Testing turn-around time

(TAT) was calculated from the time the specimen was accessioned to the time the resultwas received from the performing lab.

The billing charges associated with infectious disease testing for patients in this 138 study were evaluated using the hospital fee schedule. In order to standardize cost 139 estimates across both health systems, the UW hospital chargemaster from November 140 2020 was used for both UW and Utah patients²³. For Utah patients who received testing 141 not available on the UW chargemaster, estimated cost of microbiology testing was 142 143 obtained using the ARUP cost estimator tool (https://www.aruplab.com/testing/resources/calculator). Costs between the UW 144 chargemaster and the ARUP cost estimator tool were generally very similar for tests 145 offered by both institutions which also matched closely with the Medicare 146 reimbursement schedule. Only microbiological diagnostic costs from the hospitalization 147 during which mNGS was ordered were included in the analysis, except for one patient 148 149 who had two hospitalizations 9 days apart for the same clinical syndrome and has tests from both stays included. 150 Data was analyzed in R (v4.2). Statistical tests performed included Pearson's 151 152 Chi-squared test with Yates' continuity correction and Welch's two sample t-tests.

153 Statistical significance was set at a threshold of p <0.05.

154

155 **Results**

156 Patient Demographics and mNGS Results

During the study period, a total of 80 mNGS tests met inclusion criteria, 28 from the UW hospital system and 52 from the Utah hospital system (Table 1). For the UW

cohort, mNGS testing was rejected in 12 instances. Reasons included alternative 159 testing methods available in-house (n=5), low concern for an infectious agent (n=3), and 160 a suspected pathogen already identified (n=2). Male and female individuals were 161 equally represented in both CSF mNGS cohorts; however, a higher proportion of males 162 received plasma mNGS studies (81% male vs 19% female). The plasma mNGS cohort 163 164 included a greater number of immunocompromised individuals relative to the CSF mNGS cohort (77% vs 39%). Excluding the Utah CSF mNGS group, antibiotics were 165 166 administered to over half of the individuals in each cohort prior to mNGS specimen 167 collection and in 70% of those with a positive mNGS result. At least one individual in each cohort received mNGS testing as an outpatient. 168

Clinical indications for CSF mNGS testing were limited to individuals presenting 169 with neurologic conditions which included clinical features of meningitis or encephalitis, 170 radiologically evident lesions or vasculitis, and sub-acute cognitive impairment. Plasma 171 mNGS was ordered for a wider range of indications including endovascular disease 172 such as culture negative endocarditis (50%, 13/26), neurologic dysfunction (19%, 5/26), 173 pulmonary lesions with negative microbiologic culture or contraindications for lesion 174 175 biopsy (15%, 4/26), fever of unknown origin (12%, 3/26), and liver abscess (4%, 1/26). At least one organism was detected in 19% (10/54) of CSF specimens and 65% 176 177 (17/26) of plasma specimens. Overall, plasma mNGS results were more likely to identify 178 clinically significant pathogens compared to CSF (23% vs 7%). Plasma mNGS was also more likely to identify novel pathogens compared to CSF mNGS (15% vs 0%). While 179

significant organisms from plasma were observed at twice the frequency in the UW

differences between study site results did not reach statistical significance, clinically

180

cohort (28%, n= 5) as compared to the Utah cohort (13%, n= 1). Similarly, all novel 182 mNGS results (n=4) occurred in the UW plasma CSF group. Prior antibiotic use was not 183 associated with a decreased likelihood of detecting a clinically significant pathogen. 184 Alterations in antimicrobial therapy were infrequent within the CSF mNGS cohort 185 with only one result leading to a change in therapy. Antibiotic management changes 186 187 were more frequent in the plasma mNGS cohort with 31% (8/26) of results leading to a change in management. Plasma mNGS results also demonstrated a similar impact on 188 management between Utah and UW (25% and 33%). In 44% (4/9) of cases where 189 190 mNGS results affected antibiotic management, the change was made following a negative result (n=1) or identification of a non-significant pathogen (n=3) (Supplemental 191 192 Table 1).

193 Ordering Practices and Costs for Conventional Microbiology Testing

A common criticism of mNGS is the high cost of a single test. The average cost 194 195 of plasma mNGS and CSF mNGS in this study was \$2000 and \$2900, respectively. We compared the volume and associated costs of other microbiology testing ordered for the 196 same clinical syndrome which led to use of mNGS (Figure 1). A significant difference 197 198 was seen between study sites for CSF mNGS testing (UW: 46 tests, \$6237; Utah: 26 tests, \$2812; p<0.05) but not for plasma mNGS testing (UW: 31 tests, \$3975; Utah: 21 199 200 tests, \$2715; p=0.14) (Table 2, Figure 2A). The greater number of total tests in the UW 201 CSF mNGS group was due to a comparatively higher number of tests ordered prior to mNGS testing (UW: 40; Utah: 20, p<0.05). In the period following CSF mNGS, testing 202 203 volumes were similar between sites (UW: 6; Utah: 6, p=0.89). In relative terms, mNGS 204 accounted for 30-50% of the total microbiology testing costs regardless of test or

stewardship practice (Figure 2B). While CSF mNGS was ordered earlier for Utah
patients than for UW patients (4.5 vs 14 days), the majority were discharged by the time
results were available whereas UW patients were more likely to remain inpatients (52%
vs 10%). For plasma mNGS, 0% (0/8) of Utah patients and 6% (1/18) of UW patients
were discharged at time of mNGS result.

210 Traditional microbiology orders varied relative to the type of mNGS test (CSF vs. plasma) and timing (pre vs. post-mNGS) (Table 3). For individuals undergoing CSF 211 mNGS, the two most common traditional microbiology tests were CSF culture and blood 212 213 culture. Tests that were relatively more common after CSF mNGS ordering included tissue bacterial cultures and tissue fungal cultures. For plasma mNGS orders, the most 214 common tests overall were bacterial and fungal cultures from blood. As was observed in 215 the CSF mNGS cohort, tests from invasively collected specimens such as tissue 216 217 bacterial cultures and tissue fungal cultures were ordered more frequently following plasma mNGS orders. 218

219

220 Discussion

The introduction of mNGS into clinical microbiology represents an exciting prospect for the diagnosis of infectious disease. However, the role of this technology remains a matter of discussion, as is reflected by the variable performance of mNGS in clinical practice.^{21,24} In this study we found that 19% (10/54) of CSF results and 65% (17/26) or plasma results were positive but only 2% (1/54) of CSF results and 31% (8/26) of plasma results led to a change in antimicrobial therapy. Stewardship was not associated with a statistically higher rate of results which changed management. These

results are similar to other studies which have demonstrated a low return of clinically
 actionable results from mNGS.^{10,12,14}

While improving diagnostic yields may prove challenging, a more attainable goal 230 for stewardship programs can be the reduction of low-yield testing. The advantages of 231 stewardship are best highlighted when comparing CSF mNGS patient populations 232 233 between Utah and UW. At Utah, where ordering was not regulated, 68% (30/44) of patients were either tested as outpatients or discharged by the time results were 234 available. This stands in contrast to UW where only 20% (2/10) met these criteria. It 235 236 could be argued that one potential benefit of the policy at Utah was that mNGS was performed earlier (4 vs. 14 days) and with fewer traditional microbiology studies (26 vs. 237 46) relative to UW, thus increasing the likelihood of yielding novel or actionable results. 238 However, within the Utah cohort no novel diagnoses were made and antibiotic 239 management was only affected in one case following a negative result. 240 241 The CSF mNGS test was developed to detect esoteric and infrequent pathogens in patients with a high likelihood of unexplained infectious meningitis/encephalitis. 242 However, in a significant number of cases the assay was used as part of a 'rule-out' 243 244 approach prior to initiation of biologics for autoimmune encephalitis. Limiting these orders is critically important as data suggest that CSF mNGS may not achieve the 245 246 sensitivity sufficient to rule-out infection as compared to traditional microbiological diagnostics.^{1,14} In our data, we also observed a high rate of non-clinically significant 247 organisms identified from plasma mNGS. Reducing the risk of potential false positive 248 249 and false negative results is best achieved by limiting mNGS studies to populations with 250 a high pre-test probability of infection.^{12,14}

Interestingly, we observed a significantly longer TAT for plasma mNGS at UW as compared to Utah. We hypothesize that specimens were collected and then held while the expert committee reviewed the case and/or awaited results from pending, conventional microbiology tests. If correct, the additional time due to stewardship activities may account for the longer TAT at UW.

256 This study provides a starting point for analyzing the impact of stewardship on the overall cost of microbiology testing in patients receiving mNGS. While the total 257 258 microbiology testing costs were lower per individual in the unsupervised setting at Utah, 259 this fails to account for cost saving generated by avoiding unnecessary mNGS studies in low-yield patients. For this reason, costs saving should be assessed at the systems 260 level and not the patient level. Another important finding of our study is that the cost of a 261 single mNGS assay is similar to the total cost of all other microbiology tests ordered. 262 Therefore, requiring more traditional microbiology testing prior to mNGS ordering is 263 264 likely a cost-effective policy. However, this approach risks potential delays in diagnosis if negative cultures or finalized results are required prior to mNGS approval. Specific 265 clinical use cases for mNGS and pre-requisite traditional microbiology studies should be 266 267 established in a multidisciplinary process prior to testing.

Several limitations exist in this study; first is the retrospective nature of the data collected and the post-hoc assessment of mNGS results on antibiotic management. We attempted to use a narrow, but well-defined criteria that could be supported by the clinical record. However, mNGS results may be assessed for much wider clinical impacts and the impact of a negative result may be difficult to determine from the clinical record.¹⁴ Specifically, assessing the clinical impact of a negative CSF result from

a patient with a pre-existing low probability of infection remains challenging and will
require studies constructed to examine this question. While this study provides cost
estimates from two different hospital systems, it is possible these estimates may not be
widely generalizable between hospital systems. Individual nuances including clinical
service leadership and physician ordering practices hinder direct comparisons to this
study. It is important for any system considering mNGS stewardship to realize policies
will need to be built on an individual basis and tailored to the patient population.

This study provides several lessons for developing mNGS stewardship policies. 281 282 First, clinical performance may not be the primary endpoint to evaluate the success of mNGS stewardship as the likelihood of positive results or changes in management are 283 low regardless of approach. Instead, programs should focus on reducing testing in low-284 value situations, specifically for patients who will be discharged prior to the results 285 becoming available and in patients for whom "rule-out" testing is requested. This latter 286 287 situation was commonly observed when patients underwent CSF mNGS studies prior to initiation of immunosuppressants. Examining the financial impacts of mNGS 288 stewardship should be examined in aggregate, and costs savings associated with 289 290 preventing low-yield mNGS testing should be noted. The threshold for suggesting additional pathogen-directed testing prior to mNGS should be low given mNGS may 291 292 account for 30-50% of total testing costs while marginally improving detection of novel 293 pathogens. Finally, decisions for mNGS send-out testing approval should be made expeditiously to prevent testing delays. 294

295

296 **References**

- (1) Blauwkamp, T. A.; Thair, S.; Rosen, M. J.; Blair, L.; Lindner, M. S.; Vilfan, I. D.;
 Kawli, T.; Christians, F. C.; Venkatasubrahmanyam, S.; Wall, G. D.; Cheung, A.;
 Rogers, Z. N.; Meshulam-Simon, G.; Huijse, L.; Balakrishnan, S.; Quinn, J. V.;
- Hollemon, D.; Hong, D. K.; Vaughn, M. L.; Kertesz, M.; Bercovici, S.; Wilber, J. C.;
- Yang, S. Analytical and Clinical Validation of a Microbial Cell-Free DNA
- Sequencing Test for Infectious Disease. *Nat. Microbiol.* **2019**, *4* (4), 663–674. https://doi.org/10.1038/s41564-018-0349-6.
- 304 (2) Miller, S.; Naccache, S. N.; Samayoa, E.; Messacar, K.; Arevalo, S.; Federman, S.;
- Stryke, D.; Pham, E.; Fung, B.; Bolosky, W. J.; Ingebrigtsen, D.; Lorizio, W.; Paff,
 S. M.; Leake, J. A.; Pesano, R.; DeBiasi, R.; Dominguez, S.; Chiu, C. Y. Laboratory
 Validation of a Clinical Metagenomic Sequencing Assay for Pathogen Detection in
 Cerebrospinal Fluid. *Genome Res.* 2019. https://doi.org/10.1101/gr.238170.118.
- (3) Chiu, C. Y.; Miller, S. A. Clinical Metagenomics. *Nat. Rev. Genet.* 2019, 20 (6),
 341–355. https://doi.org/10.1038/s41576-019-0113-7.
- (4) Zhou, Y.; Wylie, K. M.; El Feghaly, R. E.; Mihindukulasuriya, K. A.; Elward, A.;
 Haslam, D. B.; Storch, G. A.; Weinstock, G. M. Metagenomic Approach for
 Identification of the Pathogens Associated with Diarrhea in Stool Specimens. *J. Clin. Microbiol.* 2016, *54* (2), 368–375. https://doi.org/10.1128/JCM.01965-15.
- (5) Huang, J.; Jiang, E.; Yang, D.; Wei, J.; Zhao, M.; Feng, J.; Cao, J. Metagenomic
 Next-Generation Sequencing versus Traditional Pathogen Detection in the
 Diagnosis of Peripheral Pulmonary Infectious Lesions. *Infect. Drug Resist.* 2020,
 13, 567–576. https://doi.org/10.2147/IDR.S235182.
- (6) Greninger, A. L.; Naccache, S. N. Metagenomics to Assist in the Diagnosis of
 Bloodstream Infection. J. Appl. Lab. Med. 2019, 3 (4), 643–653.
 https://doi.org/10.1373/jalm.2018.026120.
- (7) Farnaes, L.; Wilke, J.; Ryan Loker, K.; Bradley, J. S.; Cannavino, C. R.; Hong, D.
 K.; Pong, A.; Foley, J.; Coufal, N. G. Community-Acquired Pneumonia in Children:
 Cell-Free Plasma Sequencing for Diagnosis and Management. *Diagn. Microbiol. Infect. Dis.* 2019, 94 (2), 188–191.
- 326 https://doi.org/10.1016/j.diagmicrobio.2018.12.016.
- (8) Rakeman, J. L.; Bui, U.; Lafe, K.; Chen, Y.-C.; Honeycutt, R. J.; Cookson, B. T.
 Multilocus DNA Sequence Comparisons Rapidly Identify Pathogenic Molds. *J. Clin. Microbiol.* 2005, 43 (7), 3324–3333. https://doi.org/10.1128/JCM.43.7.3324 3333.2005.
- (9) Salipante, S. J.; Sengupta, D. J.; Rosenthal, C.; Costa, G.; Spangler, J.; Sims, E.
 H.; Jacobs, M. A.; Miller, S. I.; Hoogestraat, D. R.; Cookson, B. T.; McCoy, C.;
 Matsen, F. A.; Shendure, J.; Lee, C. C.; Harkins, T. T.; Hoffman, N. G. Rapid 16S
- rRNA Next-Generation Sequencing of Polymicrobial Clinical Samples for Diagnosis of Complex Bacterial Infections. *PloS One* **2013**, *8* (5), e65226.
- 336 https://doi.org/10.1371/journal.pone.0065226.
- (10) Lee, R. A.; Al Dhaheri, F.; Pollock, N. R.; Sharma, T. S. Assessment of the Clinical
 Utility of Plasma Metagenomic Next-Generation Sequencing in a Pediatric Hospital
 Population. J. Clin. Microbiol. 2020, 58 (7). https://doi.org/10.1128/JCM.00419-20.
 - 15

- (11) Hong, D. K.; Blauwkamp, T. A.; Kertesz, M.; Bercovici, S.; Truong, C.; Banaei, N.
 Liquid Biopsy for Infectious Diseases: Sequencing of Cell-Free Plasma to Detect
 Pathogen DNA in Patients with Invasive Fungal Disease. *Diagn. Microbiol. Infect.* Dis 2018, 02 (2) 210, 213, https://doi.org/10.1016/i.diagmicrobio.2018.06.000
- *Dis.* **2018**, 92 (3), 210–213. https://doi.org/10.1016/j.diagmicrobio.2018.06.009. (12) Rossoff, J.; Chaudhury, S.; Soneji, M.; Patel, S. J.; Kwon, S.; Armstrong, A.; Muller,
- W. J. Noninvasive Diagnosis of Infection Using Plasma Next-Generation
 Sequencing: A Single-Center Experience. *Open Forum Infect. Dis.* 2019, 6
 (ofz327). https://doi.org/10.1093/ofid/ofz327.
- (13) Wu, J.; Song, W.; Yan, H.; Luo, C.; Hu, W.; Xie, L.; Shen, N.; Cao, Q.; Mo, X.; An,
 K.; Tao, Y. Metagenomic Next-Generation Sequencing in Detecting Pathogens in
 Pediatric Oncology Patients with Suspected Bloodstream Infections. *Pediatr. Res.* 2024, 95 (3), 843–851. https://doi.org/10.1038/s41390-023-02776-y.
- (14) Hogan, C. A.; Yang, S.; Garner, O. B.; Green, D. A.; Gomez, C. A.; Dien Bard, J.;
 Pinsky, B. A.; Banaei, N. Clinical Impact of Metagenomic Next-Generation
- Sequencing of Plasma Cell-Free DNA for the Diagnosis of Infectious Diseases: A
 Multicenter Retrospective Cohort Study. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* 2021, 72 (2), 239–245. https://doi.org/10.1093/cid/ciaa035.
- (15) Lieberman, J. A.; Naureckas Li, C.; Lamb, G. S.; Kane, D. A.; Stewart, M. K.;
- Mamedov, R. A.; Cookson, B. T.; Salipante, S. J. Case Report: Comparison of
 Plasma Metagenomics to Bacterial PCR in a Case of Prosthetic Valve
 Endocarditis. *Front. Pediatr.* 2020, *8*, 575674.
- 361 https://doi.org/10.3389/fped.2020.575674.
- (16) Wilson, M. R.; Sample, H. A.; Zorn, K. C.; Arevalo, S.; Yu, G.; Neuhaus, J.;
- 363 Federman, S.; Stryke, D.; Briggs, B.; Langelier, C.; Berger, A.; Douglas, V.;
- Josephson, S. A.; Chow, F. C.; Fulton, B. D.; DeRisi, J. L.; Gelfand, J. M.;
- Naccache, S. N.; Bender, J.; Dien Bard, J.; Murkey, J.; Carlson, M.; Vespa, P. M.;
- Vijayan, T.; Allyn, P. R.; Campeau, S.; Humphries, R. M.; Klausner, J. D.; Ganzon,
- 367 C. D.; Memar, F.; Ocampo, N. A.; Zimmermann, L. L.; Cohen, S. H.; Polage, C. R.;
- 368 DeBiasi, R. L.; Haller, B.; Dallas, R.; Maron, G.; Hayden, R.; Messacar, K.;
- 369 Dominguez, S. R.; Miller, S.; Chiu, C. Y. Clinical Metagenomic Sequencing for
- Diagnosis of Meningitis and Encephalitis. *N. Engl. J. Med.* 2019, 380 (24), 2327–
 2340. https://doi.org/10.1056/NEJMoa1803396.
- (17) Batool, M.; Galloway-Peña, J. Clinical Metagenomics—Challenges and Future
 Prospects. *Front. Microbiol.* 2023, *14*, 1186424.
- https://doi.org/10.3389/fmicb.2023.1186424.
- (18) Goggin, K. P.; Fox, T. G.; Jaggi, P.; Shane, A. L.; Gonzalez, M. D. Impact of a New
 Diagnostic Stewardship Team on Utilization and Interpretation of a Microbial CellFree DNA Detection Test. *J. Pediatr. Infect. Dis. Soc.* 2023, *12* (Supplement_1),
 S24. https://doi.org/10.1093/jpids/piad070.049.
- (19) Gaston, D. C.; Chiang, A. D.; Dee, K.; Dulek, D.; Banerjee, R.; Humphries, R. M.
 Diagnostic Stewardship for Next-Generation Sequencing Assays in Clinical
 Microbiology: An Appeal for Thoughtful Collaboration. *Clin. Lab. Med.* 2024, 44 (1),
 63–73. https://doi.org/10.1016/j.cll.2023.10.002.
- (20) Morjaria, S.; Chapin, K. C. Who to Test, When, and for What: Why Diagnostic
 Stewardship in Infectious Diseases Matters. J. Mol. Diagn. 2020, 22 (9), 1109–
- ³⁸⁵ 1113. https://doi.org/10.1016/j.jmoldx.2020.06.012.

- (21) Miller, S.; Chiu, C.; Rodino, K. G.; Miller, M. B. Point-Counterpoint: Should We Be
 Performing Metagenomic Next-Generation Sequencing for Infectious Disease
 Diagnosis in the Clinical Laboratory? *J. Clin. Microbiol.* **2019**, *58* (3), e01739-19,
- 389 /jcm/58/3/JCM.01739-19.atom. https://doi.org/10.1128/JCM.01739-19.
- (22) Heldman, M. R.; Ahmed, A. A.; Liu, W.; Vo, A.; Keane-Candib, J.; Stevens-Ayers,
 T.; Boeckh, M.; Blauwkamp, T. A.; Fisher, C. E.; Hill, J. A. Serial Quantitation of
 Plasma Microbial Cell-Free DNA Before and After Diagnosis of Pulmonary Invasive
- Mold Infections After Hematopoietic Cell Transplant. *J. Infect. Dis.* **2024**, *229* (2), 576–587. https://doi.org/10.1093/infdis/jiad255.
- (23) Batty, M.; Ippolito, B. Mystery Of The Chargemaster: Examining The Role Of
 Hospital List Prices In What Patients Actually Pay. *Health Aff. Proj. Hope* 2017, 36
 (4), 689–696. https://doi.org/10.1377/hlthaff.2016.0986.
- 398 (24) Babady, N. E. Clinical Metagenomics for Bloodstream Infections: Is the Juice
- Worth the Squeeze? *Clin. Infect. Dis.* **2021**, 72 (2), 246–248.
- 400 https://doi.org/10.1093/cid/ciaa041.
- 401

| | CSF | | | Plasma | | |
|---------------------------------|------------|------------|------------|------------|------------|------------|
| | Utah | UW | Total | Utah | UW | Total |
| Individuals | 44 | 10 | 54 | 8 | 18 | 26 |
| Median Age (IQR) | 45 (33-46) | 47 (34-51) | 45 (35-64) | 52 (41-49) | 52 (41-57) | 53 (41-62) |
| Sex (n, [%]) | | | | | | |
| Male | 18 (41%) | 4 (40%) | 22 (41%) | 8 (100%) | 13 (72%) | 21 (81%) |
| Female | 26 (59%) | 6 (60%) | 32 (59%) | 0 (0%) | 5 (28%) | 5 (19%) |
| Clinical Information (n, [%]) | | | | | | |
| Immunosuppressed | 15 (34%) | 4 (40%) | 21 (39%) | 7 (88%) | 13 (72%) | 20 (77%) |
| Received antibiotics | 12 (27%) | 8 (80%) | 20 (37%) | 5 (63%) | 17 (94%) | 22 (85%) |
| Outpatient | 7 (16%) | 1 (10%) | 8 (15%) | 1 (13%) | 2 (11%) | 3 (12%) |
| Clinical Indication (n, [%]) | | | | | | |
| Neurologic | 44 (100%) | 10 (100%) | 54 (100%) | 4 (50%) | 1 (6%) | 5 (19%) |
| Endovascular | 0 (0%) | 0 (0%) | 0 (0%) | 2 (25%) | 11 (61%) | 13 (50%) |
| Pulmonary | 0 (0%) | 0 (0%) | 0 (0%) | 1 (13%) | 3 (17%) | 4 (15%) |
| FUO | 0 (0%) | 0 (0%) | 0 (0%) | 1 (13%) | 2 (11%) | 3 (12%) |
| Results (n, [%]) | | | | | | |
| Positive mNGS results | 10 (23%) | 0 (0%) | 10 (19%) | 6 (75%) | 11 (61%) | 17 (65%) |
| Clinically significant | 4 (9%) | 0 (0%) | 4 (7%) | 1 (13%) | 5 (28%) | 6 (23%) |
| Novel | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (22%) | 4 (15%) |
| Change in antibiotic management | 1 (2%) | 0 (0%) | 1 (2%) | 2 (25%) | 6 (33%) | 8 (31%) |

Table 1 - Demographic and Clinical Information for Individuals Receiving mNGS

Table 2 - Traditional Microbiology Test Volume and Cost for Individuals Receiving mNGS

| | CSF | | | Plasma | | | |
|-----------------------------------|-------------|-------------|---------|-------------|-------------|---------|--|
| | Utah | UW | p-value | Utah | UW | p-value | |
| Micro tests ordered (mean, [SD]) | | | | | | | |
| Total | 26 (18) | 46 (18) | 0.01 | 21 (8) | 31 (25) | 0.14 | |
| Pre-mNGS | 20 (12) | 40 (15) | 0.005 | 16 (8) | 23 (13) | 0.15 | |
| Post-mNGS | 6 (12) | 6 (4) | 0.89 | 5 (6) | 9 (19) | 0.43 | |
| Cost (mean, [SD]) | | | | | | | |
| Total | 2812 (2007) | 6237 (2923) | 0.008 | 2715 (1223) | 3975 (524) | 0.37 | |
| Pre-mNGS | 2147 (1392) | 5123 (2160) | 0.003 | 2125 (1096) | 2399 (1965) | 0.67 | |
| Post-mNGS | 665 (1171) | 811 (878) | 0.67 | 589 (804) | 1575 (4552) | 0.41 | |
| mNGS ordering | | | | | | | |
| Hospital Day mNGS ordered (range) | 4.5 (0-21) | 14 (2-80) | 0.03 | 12 (7-24) | 6.5 (2-24) | 0.38 | |
| Median TAT, days (range) | 14 (9-26) | 14 (6-21) | 0.65 | 1 (1-4) | 3 (2-7) | 0.05 | |
| Discharged at time of result, n | 23 | 1 | 0.03 | 0 | 1 | 0.79 | |

| | | CSF | | | | |
|-----------------------------------|--------|-----------------------------------|--------|------------------------------|--------|--|
| Pre-mNGS | | Post-mNGS | Total | | | |
| Test | Number | Test | Number | Test | Number | |
| CSF culture | 81 | AFB culture | 17 | CSF culture | 92 | |
| Blood culture | 64 | Blood culture | 17 | Blood culture | 83 | |
| HSV PCR | 55 | Tissue culture 1 | | AFB culture with stain | 68 | |
| AFB culture | 51 | CSF culture | | HSV PCR | 63 | |
| VZV EIA | 48 | CMV PCR 10 | | Cryptococcal Antigen | 53 | |
| Cryptococcal Antigen | 47 | Tissue fungal culture 10 | | VZV EIA | 51 | |
| CSF multiplex PCR | 45 | Bacterial culture, body fluid 9 | | CSF multiplex PCR | 48 | |
| CSF fungal culture | 40 | CSF culture, anaerobic | | CMV PCR | 44 | |
| VZV PCR | 38 | HSV PCR | 8 | CSF fungal culture | 44 | |
| CMV PCR | 34 | Coccidioides Ab compfix | 8 | VZV PCR | 44 | |
| | | Plasma | | | | |
| Pre-mNGS | | Post-mNGS | | Total | | |
| Test | Number | Test | Number | Test | Number | |
| Blood culture | 128 | Blood culture | 20 | Blood culture | 148 | |
| Blood fungal culture | 27 | Broad-range fungal PCR | 15 | Blood fungal culture | 28 | |
| AFB culture | 13 | M. tb complex PCR | 14 | AFB culture | 25 | |
| Aspergillus galactomanin EIA | 12 | Broad-range bacterial PCR | 14 | Broad-range fungal PCR | 22 | |
| Urine Culture | 11 | AFB culture | 12 | Broad-range bacterial PCR | 20 | |
| Brucella Ab screen, agglutination | 9 | Tissue culture | 12 | Tissue culture | 19 | |
| Bartonella Ab panel | 9 | NTM PCR | 12 | M. tb complex PCR | 1 | |
| Q fever Ab, IgG and IgM | 9 | Tissue fungal with direct exam | 6 | NTM PCR | 1 | |
| EBV quant PCR | 8 | Wound culture, anaerobic | 4 | Urine Culture | 1 | |
| Nocardia Culture | 7 | Brucella Ab screen, agglutination | 3 | Aspergillus galactomanan EIA | 1 | |

Table 3 - Most Common Traditional Microbiology Tests Ordered for Individuals Receiving mNGS






Figure 1. - Total and Relative Volumes of Traditional Microbiology Test Orders for Patients 411 **Receiving mNGS** 412


A) Traditional microbiology testing volumes for patients undergoing CSF or plasma mNGS 413

studies. Results separated by study site and test. Box and whisker plot represents mean, IQR, 414

and 95th percentile. B) Average proportion of total traditional microbiology tests ordered before 415

and after plasma or CSF mNGS at Utah and UW. The mNGS order represents the relative size 416

of a single test order. 417



420 **Figure 2.** - Total and Relative Cost of Traditional Microbiology Test Orders for Patients

421 Receiving mNGS

422 A) Traditional microbiology testing costs for patients undergoing CSF or plasma mNGS studies.

423 Results separated by study site and test. Box and whisker plot represents mean, IQR, and 95th

424 percentile. B) Cost of traditional and mNGS orders relative to the overall microbiology testing

425 expenditure.